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Antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) is a group of systemic vasculitides, that are charac-
terized by inflammation in the small vessels, ranging from capillaries to arterioles or venules. AAV is divided into three variants 
based on the clinical manifestations and histological findings such as microscopic polyangiitis (MPA), granulomatosis with pol-
yangiitis (GPA) and eosinophilic GPA (EGPA). MPA often induces rapid progressive necrotising glomerulonephritis, and occa-
sionally induces diffuse alveolar hemorrhage. In contrast, GPA preferentially affects the respiratory tracts from the bronchus to 
the nasal cavity. GPA can also involve the kidneys, but the frequency of renal involvement is less than MPA. EGPA is based on 
allergic components such as asthma, peripheral eosinophilia, migratory eosinophilic pneumonia and eosinophil infiltration. 
Since 1982, when the association between ANCA and systemic vasculitis was first reported, several classification criteria for 
AAV have been proposed. This review describes the classification criteria for and nomenclature of AAV from the 1990 
American College of Rheumatology (ACR) classification criteria to the 2012 revised Chapel Hill consensus conference (CHCC) 
nomenclature of Vasculitides. New classification trials for AAV such as AAV based on the ANCA-types (myeloperoxidase- 
ANCA vasculitis, proteinase 3-ANCA vasculitis and ANCA negative vasculitis) and the ACR/European League Against 
Rheumatism (EULAR) 2017 provisional classification criteria for GPA were also introduced. In addition, the histopathological 
classification of ANCA-associated glomerulonephritis and the revised 2017 international consensus on testing of ANCAs in 
GPA and MPA are also discussed. (J Rheum Dis 2019;26:156-164)
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INTRODUCTION
Systemic vasculitides are generally categorized based on 
the size of the vessels affected. Large vessel vasculitis in-
cludes Takayasu arteritis and giant cell arteritis and me-
dium vessel vasculitis consists of polyarteritis nodosa 
(PAN) and Kawasaki disease. Small vessel vasculitis is 
divided into two groups based on immune deposits in the 
affected organ-tissues such as antineutrophil cytoplasmic 
antibody (ANCA)-associated vasculitis (AAV) and im-
mune complex small vessel vasculitis. Immune complex 
small vessel vasculitis includes cryoglobulinemic vasculi-
tis, immunoglobulin A (IgA) vasculitis (Henoch-Schönlein 
purpura, HSP) and hypocomplementemic urticarial vas-
culitis (Anti-C1q vasculitis). Capillaritis in the lungs and 
kidneys, which manifests as diffuse alveolar hemorrhage 
or glomerulonephritis, rarely occurs in medium vessel 
vasculitis such as PAN. Behçet's disease can involve 
small, medium and large vessels, so it is called variable 
vessel vasculitis [1,2].  AAV is a group of systemic vasculi-
tides, which is characterized by inflammation in the small 
vessels ranging from capillaries to arterioles or venules. 
The histological features of AAV are mainly necrotizing 
vasculitis with few or no immune deposits on the affected 
organs [3,4]. AAV is also distributed to three variants 
based on the clinical manifestations and histological find-
ings, such as microscopic polyangiitis (MPA), gran-
ulomatosis with polyangiitis (GPA), and eosinophilic 
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Table 1. The 1990 American College of Rheumatology classification criteria for antineutrophil cytoplasmic antibody-associated 
vasculitis and polyarteritis nodosa
Eosinophilic granulomatosis 
with polyangiitis 
(Churg-Strauss syndrome)
Granulomatosis 
with polyangiitis 
(Wegener’s granulomatosis)
Microscopic 
polyangiitis 
Polyarteritis nodosa 
1) Asthma (histology) 
2) Peripheral eosinophilia 
(＞10% of peripheral blood) 
3) Mono or polyneuropathy 
4) Pulmonary infiltrates (non-fixed)
5) Paranasal sinus abnormality
6) Extravascular eosinophils 
on histology 
1) Nasal or oral inflammation 
2) Chest radiograph (nodules, 
fixed infiltrates or cavities)
3) Micro-haematuria or red blood
cell casts in urine sediment
4) Granulomatous inflammation 
on histology 
None 1) Weight loss ＞4 kg
2) Livedo reticularis
3) Testicular pain/tenderness
4) Myalgia, weakness or leg tender-
ness 
5) Mono or polyneuropathy
6) Diastolic blood pressure 
＞90 mmHg
7) Elevation of blood urea nitrogen ＞40
mg/dL or creatinine ＞1.5 mg/dL
8) Presence of hepatitis B surface 
antigen or antibody in serum 
9) Arteriogram showing aneurysms or 
occlusions of the visceral arteries
10) Biopsy of small or medium-sized 
artery containing polymorphonuclear 
cells 
4 items or greater are met 2 items or greater are met 3 items or greater are met
Sensitivity 85.0%
Specificity 99.7%
Sensitivity 88.2%
Specificity 92.0%
Sensitivity 82.2%
Specificity 86.6%
GPA (EGPA) [1,5]. GPA, which was first introduced and 
formerly known as Wegener’s granulomatosis (WG) [6], 
describes the pathological features, so GPA is recom-
mended name. EGPA and Churg-Strauss syndrome (CSS) 
are use identically [1]. MPA often induces rapid pro-
gressive necrotizing glomerulonephritis, and occasion-
ally induces diffuse alveolar hemorrhage [7]. In contrast, 
GPA preferentially affects the respiratory tract from the 
bronchus to the nasal cavity. GPA can also involve the kid-
neys, even though the frequency of renal involvement is 
less than MPA. Among the three AAV variants, cartilagi-
nous involvement is observed mainly in GPA and is de-
fined as inflamed ear or nose cartilage or hoarse voice/ 
stridor, endobronchial involvement or saddle nose de-
formity [8]. EGPA is based on allergic components, such 
as asthma, peripheral eosinophilia, migratory eosino-
philic pneumonia and eosinophil infiltration [9,10]. 
Thus far, there have been many efforts to develop diag-
nostic methods to classify and confirm AAV. ANCA ap-
pears to be closely related to AAV, but, not all AAV pa-
tients have ANCA and the rate of ANCA detection is low-
er than expected: myeloperoxidase (MPO)-ANCA is de-
tected in 30%∼80% of MPA patients, 0%∼10% of GPA 
patients and 32%∼92% of EGPA patients, whereas, pro-
teinase 3 (PR3)-ANCA is detected in 10%∼20% of MPA 
patients, 40%∼95% of GPA patients and 0%∼3.2% of 
EGPA patients [11]. Moreover, there is currently no 
method that is conclusive in helping to classify AAV. For 
these reasons, the various clinical classification criteria 
have been developed, proposed and validated. The classi-
fication criteria are different from the diagnostic criteria. 
The former is defined as observations that classify a spe-
cific patient into a standardized category for study, where-
as the latter is defined as observations that demonstrate 
or confidently predict the presence of the defining fea-
tures of the disease in a specific patient. This review in-
troduces the classification criteria for AAV proposed to 
date.
MAIN SUBJECTS
1990 American College of Rheumatology (ACR) 
classification criteria and 1994 Chapel Hill consensus 
conference (CHCC) nomenclature of systemic 
vasculitides
The 1990 ACR classification criteria (the 1990 ACR cri-
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teria) provide the classification criteria for EGPA, GPA 
and PAN but not MPA [12-14]. The 1990 ACR criteria for 
AAV and PAN are summarized in Table 1. The 1990 ACR 
criteria for EGPA consist of six items as follows: i) asthma 
(or history of asthma), ii) peripheral eosinophilia, iii) 
mono or polyneuropathy, iv) non-fixed pulmonary in-
filtrates, v) abnormality of paranasal sinus, and vi) ex-
travascular eosinophil infiltration on histology. EGPA can 
be classified firmly when four items or greater are met 
[13]. The 1990 ACR criteria for GPA comprise 4 items as 
follows: i) nasal or oral inflammation, ii) nodular, fixed or 
cavitary pulmonary involvement, iii) urinary abnormality 
(microhaematuria or red blood cell casts), iv) gran-
ulomatous inflammation on histology. GPA can be classi-
fied when two items or greater are satisfied [12]. The 
1990 ACR criteria had several limitations. The 1990 ACR 
criteria provide those for PAN rather than MPA [14]. 
They did not include other vasculitides, which should be 
differentiated from AAV, such as primary central nervous 
system vasculitis, Cogan’s syndrome and cry-
oglobulinemic vasculitis. In addition, they could not dis-
tinguish vasculitis from vasculitis-mimicking diseases. 
In 1994, the CHCC nomenclature of systemic vasculi-
tides (the 1994 CHCC definitions) was proposed. The 
1994 CHCC definitions provided standardized nomen-
clature of vasculitides and subgroups using a general and 
widely used terminology. Unlike the 1990 ACR criteria, 
the 1994 CHCC definitions defined PAN and MPA 
separately. They described PAN as necrotizing inflamm-
ation of the medium-sized or small arteries without glo-
merulonephritis or vasculitis in the arterioles, capillaries 
or venules. In contrast, they described MPA as necrotiz-
ing vasculitis, with few or no immune deposits affecting 
the small vessels (capillaries, venules and arterioles). In 
addition, they added a comment that MPA may involve 
the small and medium-sized arteries and MPA exhibits 
commonly present glomerulonephritis and often pulmo-
nary capillaritis [2]. In other words, PAN and MPA might 
be a common range in that their histological feature is ne-
crotizing vasculitis and both can partially share the size of 
the vessels affected. On the other hand, clinical manifes-
tations due to capillaritis such as glomerulonephritis and 
diffuse alveolar hemorrhage may be critical clues to sug-
gest MPA. The 1994 CHCC definitions also had several 
limitations. They included ANCA tests, which were not 
included in the 1990 ACR criteria, but they did not pro-
vide a predictive value of ANCA to differentiate AAV 
from other vasculitides. The 1994 CHCC definitions were 
based primarily on the histological features. Hence, they 
could not be applied to patients who did not undergo 
biopsy. Moreover, the rate of the reclassification in MPA 
and GPA patients was not high. 
2007 European Medicine Agency (EMA) algorithm 
for the classification of AAV and PAN
In 2007, a new algorithm for the classification of AAV 
and PAN was proposed by the EMA. There are three re-
quirements for initiating the 2007 EMA algorithm for the 
classification of AAV and PAN (the 2007 EMA algo-
rithm). The first requirement is the follow-up duration 
for 3 months or greater. The second requirement is the 
age of onset over 16 years old. The third requirement 
should meet all three of the following: A) symptoms and 
signs compatible with AAV or PAN; B) at least one of the 
following: i) histological proof of vasculitis, ii) ANCA 
positivity, and iii) specific investigations strongly sugges-
tive of vasculitis or granuloma such as neurophysiology, 
angiography or magnetic resonance imaging. Both IgA 
deposits and anti-glomerular basement membrane (GBM) 
antibodies may occur concurrently with AAV, iv) eosino-
philia (＞10% or ＞1.5×109/L); C) no other diagnosis to 
account for the symptoms and signs such as malignancy, 
infection (hepatitis B and C virus, tuberculosis), drugs 
(hydralazine, propylthiouracil, cocaine), other vasculi-
tides and vasculitis mimics [5]. According to the third re-
quirement, HSP and anti-GBM disease can occur simulta-
neously with AAV, but also play a role in excluding AAV. 
Therefore, a precise diagnosis of AAV must depend on the 
physicians’ decisions. 
In addition, the 2007 EMA algorithm suggests surrogate 
markers for WG (GPA), which involve lower airways, in-
cluding i) X-ray evidence of fixed pulmonary infiltrates, 
nodules or cavitations present for ＞1 month and ii) bron-
chial stenosis. Surrogate markers involving the upper air-
ways include i) bloody nasal discharge and crusting for ＞
1 month or nasal ulceration, ii) chronic sinusitis, otitis 
media or mastoiditis for ＞3 months, iii) retro-orbital 
mass or inflammation (pseudotumour), iv) subglottic 
stenosis and v) saddle nose deformity/destructive sino-
nasal disease. Among several surrogate markers for GPA, 
only one surrogate marker is necessary. The 2007 EMA al-
gorithm also provides surrogate markers for renal vasculi-
tis (glomerulonephritis), which are either hematuria as-
sociated with red cell casts (or ＞10% dysmorphic eryth-
rocytes) or 2+hematuria and 2+proteinuria on urinalysis 
[5]. 
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Figure 1. The 2007 EMA algorithm for AAV and PAN. EMA: the European Medicine Agency, AAV: associated vasculitis, PAN: clas-
sic polyarteritis nodosa, ACR: the American College of Rheumatology, CSS: Churg-Strauss syndrome, EGPA: eosinophilic gran-
ulomatosis with polyangiitis, WG: Wegener’s granulomatosis, CHCC: Chapel Hill consensus conference, MPA: microscopic poly-
angiitis, GPA: granulomatosis with polyangiitis, ANCA: antineutrophil cytoplasmic antibody.
The 2007 EMA algorithm for AAV and PAN was modi-
fied and depicted in Figure 1. 
Once a patient fulfils three entry requirements, the 2007 
EMA algorithm can be applied. The first step is to apply 
the 1990 ACR criteria for CSS (EGPA) to a patient. If a pa-
tient meets the 1990 ACR criteria for CSS (EGPA), a pa-
tient can be classified as EGPA and no further application 
is required. A patient can be classified as GPA by the four 
conditions as follows: i) when a patient fulfils the 1990 
ACR criteria for WG (GPA); ii) when a patient exhibits a 
histology compatible with WG (the 1994 CHCC defi-
nition); iii) when a patient exhibits a histology compat-
ible with MPA (the 1994 CHCC definition) and WG 
(GPA) surrogate markers, and iv) when a patient has WG 
(GPA) surrogate markers and ANCA in the absence of 
histology [5]. After the 1994 CHCC definitions were pro-
posed, the first condition for the classification of GPA was 
considered controversial because there might be a range 
of confounding situations to mimic GPA [1]. A patient 
can be classified as MPA by the two conditions after ex-
cluding EGPA and GPA as follows: i) when a patient ex-
hibits the clinical features and histology compatible with 
MPA in the absence of WG (GPA) surrogate markers and 
ii) when a patient has ANCA and renal vasculitis in the 
absence of histology or WG (GPA) surrogate markers [5]. 
A patient is rarely diagnosed with AAV if a patient cannot 
be classified as EGPA, GPA and MPA. A previous study, 
which validated the clinical implications of the 2007 EMA 
algorithm using the 2012 CHCC criteria, reported that 
the 2012 CHCC definitions resulted in no change to the 
performance of the EMA algorithm for the classification 
of AAV [15]. 
Revised 2012 CHCC nomenclature of vasculitides
The revised CHCC definitions were proposed in 2012. 
These definitions divided small vessel vasculitis into two 
groups such as AAV and immune complex small vessel 
vasculitis. Accordingly, the 2012 definitions officially 
used ANCA to define the categories of small vessel vascu-
litis for the first time. Based on the 2012 CHCC defi-
nitions, AAV is defined as necrotizing vasculitis, with few 
or no immune deposits, predominantly affecting the 
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Table 2. The revised 2012 Chapel Hill consensus conference nomenclature of vasculitides
Eosinophilic granulomatosis with 
polyangiitis (Churg-Strauss syndrome)
Granulomatosis with polyangiitis 
(Wegener’s granulomatosis)
Microscopic polyangiitis 
Eosinophil-rich and necrotizing 
granulomatous inflammation often 
involving the respiratory tract, and 
necrotizing vasculitis predominantly 
affecting small to medium vessels, 
and associated with asthma and 
eosinophilia. ANCA is more frequent 
when glomerulonephritis is present.
Necrotizing granulomatous inflammation 
usually involving the upper and lower 
respiratory tract, and necrotizing 
vasculitis affecting predominantly small 
to medium vessels (e.g., capillaries, 
venules, arterioles, arteries and veins). 
Necrotizing glomerulonephritis is 
common.
Necrotizing vasculitis, with few or 
no immune deposits, predominantly 
affecting small vessels (i.e., capillaries, 
venules, or arterioles). Necrotizing 
arteritis involving small and medium 
arteries may be present. Necrotizing 
glomerulonephritis is very common. 
Pulmonary capillaritis often occurs. 
Granulomatous inflammation is absent.
ANCA: antineutrophil cytoplasmic antibody. 
small vessels. AAV may be associated with ANCA but 
this association is not obligatory. Furthermore, the 2012 
CHCC definitions suggest a prefix indicating ANCA re-
activity such as MPO-ANCA, PR3-ANCA, and ANCA- 
negative, which will be discussed later in this article [1]. 
The 2012 CHCC definitions for MPA, GPA and EGPA are 
cited and summarized in Table 2. EGPA is described as eo-
sinophil-rich and necrotizing granulomatous inflamm-
ation often involving the respiratory tract, and necrotiz-
ing vasculitis predominantly affecting the small to me-
dium vessels and is associated with asthma and eosinophilia. 
GPA is described as necrotizing granulomatous in-
flammation usually involving the upper and lower respi-
ratory tract, and necrotizing vasculitis affecting predom-
inantly the small to medium vessels. MPA is described as 
necrotizing vasculitis, with few or no immune deposits, 
predominantly affecting the small vessels, such as capil-
laries, venules, or arterioles without granulomatous 
inflammation. Glomerulonephritis occurs very often in 
MPA, commonly in GPA and occasionally in EGPA. 
Pulmonary capillaritis often occurs in MPA but may occa-
sionally be observed in GPA and EGPA patients [1]. 
Modified classification criteria 
The 2007 EMA algorithm for AAV and PAN was modi-
fied by the 2012 CHCC criteria and preliminary modified 
classification criteria for AAV in Korean patients were de-
veloped, as shown in Figure 2. These criteria are based on 
the 2007 EMA algorithm but the first condition of the 
2007 EMA algorithm for GPA (Does a patient fulfil the 
1990 ACR criteria for WG [GPA]?) was deleted. In con-
trast, a condition is added in that no glomerulonephritis 
can occur in PAN, and that PAN is rarely associated with 
ANCA positivity. The first condition of the 2007 EMA al-
gorithm for GPA (Does a patient fulfil the 1990 ACR cri-
teria for WG [GPA]?) was deleted. The same surrogate 
markers suggesting WG (GPA) with those of the 2007 
EMA algorithm was used. Histopathological confirmation 
is the most critical for the classification of AAV, even 
though the absence of histology was accepted when other 
strongly suggestive clinical and laboratory data are pres-
ent such as the surrogate markers for GPA, ANCA pos-
itivity and urinalysis for hematuria and proteinuria. 
Therefore, if possible, physicians should perform a biopsy 
of the affected organ-tissues, such as the kidneys, lungs, 
nerves and nasal sinus, including nasopharyngeal masses 
[16]. 
New classification criteria for AAV
A new trial for reclassifying AAV into three variants 
based on the ANCA positivity or negativity and its types, 
such as MPO-ANCA, PR3-ANCA and ANCA negative 
vasculitis was reported recently [17]. The authors ex-
plained the background of this study for three reasons. 
First, compared to EGPA and GPA, the conditions for 
MPA of the 2007 EMA algorithm and the 2012 CHCC def-
initions are unclear [1,5,15,18]. Second, neither MPO- 
ANCA nor PR3-ANCA are not emphasized despite the 
origin of the name of AAV [1]. In addition, even the 2017 
EMA algorithm mentions ANCA positivity rather than 
MPO-ANCA positivity or PR3-ANCA positivity [5]. 
Third, recent studies have supported the distinct entities 
among MPO-ANCA, PR3-ANCA, and ANCA negative 
vasculitis [16]. This concept of a new classification meth-
od was determined by the different genetic background 
between the two epitopes. The chromosomal locus of 
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Figure 2. The modified classification criteria for AAV and PAN in Korean patients. These criteria are based on the 2007 EMA algo-
rithm but the first condition of the 2007 EMA algorithm for GPA (Does a patient fulfil the 1990 ACR criteria for WG [GPA]?) was
deleted. In contrast, a condition is added in that no glomerulonephritis can occur in PAN, and that PAN is rarely associated with
ANCA positivity. AAV: antineutrophil cytoplasmic antibody-associated vasculitis, PAN: classic polyarteritis nodosa, EMA: the 
European Medicine Agency, GPA: granulomatosis with polyangiitis, ACR: the American College of Rheumatology, WG: 
Wegener’s granulomatosis, ANCA: antineutrophil cytoplasmic antibody, EGPA: eosinophilic granulomatosis with polyangiitis, 
CHCC: Chapel Hill consensus conference, MPA: microscopic polyangiitis, PR3: proteinase 3, MPO: myeloperoxidase, GN: 
glomerulonephritis.
PR3 is 17q23.1, whereas that of MPO is 19p13.3 [19-21]. 
PR3 is expressed on the membrane surface of resting neu-
trophils whereas MPO is not expressed [22,23]. Moreover, 
PR3-ANCA consists mostly of IgG and may induce the 
weak activation of primed neutrophils in vitro, whereas 
MPO-ANCA is composed of only IgG and may induce rel-
atively strong activation [16]. In addition, MPA patients 
can exhibit different clinical manifestations at diagnosis 
or prognosis during follow-up according to MPO-ANCA 
positivity, PR3-ANCA positivity or ANCA negativity. For 
example, rituximab is more effective than cyclophosphamide 
in patients with PR3-ANCA whereas both rituximab and 
cyclophosphamide are similarly effective in patients with 
MPO-ANCA. In addition, patients with PR3-ANCA are at 
higher risk of relapse than patients with MPO-ANCA 
[24]. 
On the other hand, the diagnostic and classification cri-
teria for primary systemic vasculitis (DCVAS) and collab-
orators recently proposed the ACR/European League 
Against Rheumatism (EULAR) 2017 provisional classi-
fication criteria for GPA. These criteria include nine 
items: five items are clinical variables and four items are 
test-variables. Different weights were assigned to each 
item. The score assigned to cytoplasmic (C)-ANCA or 
PR3-ANCA was the highest among the items. In partic-
ular, nasal polyps and eosinophilia ＞10%, which favor 
EGPA, are negative contributors to the diagnosis of GPA. 
When a patient obtains a total score of five or greater, 
he/she can be classified as GPA (presented at 2016 ACR 
session: New Classification Criteria for ANCA-asso-
ciated Vasculitis: implications for clinical practice) (Table 
3). On the other hand, the 2017 provisional criteria have 
several limitations in that they did not include any items 
of kidney involvement for GPA or fixed lung infiltrates. 
Furthermore, PR3-ANCA positivity might be over-
estimated compared to the 1990 ACR criteria or the 2007 
EMA algorithm modified by the 2012 CHCC definitions. 
Therefore, the weight of PR3-ANCA positivity should be 
readjusted in the near future [25]. 
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Table 3. The 2017 Provisional ACR/EULAR classification criteria for GPA 
Items
Score for the 
ACR/EULAR 
2017 provisional 
classification 
criteria for 
GPA
Bloody nasal 
discharge, 
ulcers, 
crusting or 
sinonasal 
congestion
Nasal 
polyps
Hearing 
loss or 
reduction
Cartilaginous 
involvement
Red or 
painful 
eyes
C-ANCA 
or 
PR3-ANCA
Eosinophil 
count ≥1 
(×109/L)
Nodule, 
mass or 
cavitation 
on chest 
imaging 
Granuloma 
on biopsy
Score Sum ≥5 3 −4 1 2 1 5 −3 2 3
When a patient gets the total score of 5 or greater, he/she can be classified as GPA. ACR: the American College of Rheumatology, 
EULAR: the European League Against Rheumatism, GPA: granulomatosis, C-ANCA: cytoplasmic-antineutrophil cytoplasmic 
antibody, PR3-ANCA; proteinase 3-ANCA.
Figure 3. Histopathological classification of antineutrophil cytoplasmic antibody-associated glomerulonephritis.
Histopathological classification of ANCA-associated 
glomerulonephritis 
When AAV predominantly involves the kidneys more 
frequently than the other major organs, it is referred to as 
ANCA-associated renal vasculitis. In particular, MPA and 
GPA often induce acute and chronic glomerulonephritis 
and tubular inflammation, which are important risk fac-
tors for an impaired renal function during follow-up [11]. 
Vascular lesions and damages are also observed in kid-
ney-tissues, such as arteriosclerosis, but they have been 
considered not to commonly provoke renal impairment. 
ANCA-associated glomerulonephritis is critical for the 
classification of AAV via renal histopathology, which is 
characterized by necrotizing and crescentic glomer-
ulonephritis with little or no glomerular staining for im-
munoglobulins or immune deposits (so-called pauci-im-
mune staining pattern) [4]. Several definitions related to 
the histopathology of AAV-associated glomeruloneph-
ritis are as follows: i) normal glomeruli are defined as glo-
meruli without vasculitic lesions or global sclerosis with 
the possibility of subtle changes as a result of ischemia or 
a minimum number of inflammatory cells, ii) cellular 
crescents are defined as purely cellular lesions or with cel-
lular components, iii) fibrous crescents are defined as fi-
brotic (sclerotic) lesion with fibroblasts filling Bowman’s 
space, and iv) global glomerulosclerosis is defined as ＞
80% of the glomerulus scleroses. The classification 
scheme for ANCA-associated glomerulonephritis classi-
fies patients with ANCA-associated glomerulonephritis 
into four classes: focal (≥50% normal glomeruli), cres-
centic (≥50% cellular crescents), mixed (＜50% normal, 
＜50% crescentic, ＜50% globally sclerotic glomeruli) 
and sclerotic (≥50% globally sclerotic glomeruli). The 
histopathological findings are generally scored in the fol-
lowing order: globally sclerotic glomeruli, normal glo-
meruli, and cellular crescents (Figure 3) [3,26]. The his-
topathological classification of ANCA-associated glo-
merulonephritis has an important influence on the renal 
outcomes [27]. The incidence rates of estimated glomer-
ular filtration rate ＜15 or on dialysis within the first 1 
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year of focal, crescentic, mixed and sclerotic are 0%, 15%, 
25%, and 31%, respectively (Figure 3) [3]. 
Revised 2017 international consensus on testing 
of ANCAs in GPA and MPA
Screening tests for ANCAs are commonly performed for 
the classification of GPA and MPA in suspicious patients 
in real clinical settings. The association between ANCA 
and systemic vasculitis was first reported in 1982 [28], 
and the first observation of C-ANCA in GPA patients was 
made in 1985 [29]. In 1988 and 1989, MPO and PR3 were 
identified as autoantigens of ANCAs and P-ANCA was 
detected in GPA patients [30,31]. The 1999 international 
consensus statement on the testing and reporting of 
ANCA recommended that indirect immunofluorescence 
(IIF) should be performed as an initial screening method 
to detect ANCAs in patients suspected of systemic 
vasculitis. When ANCAs are detected, it was recom-
mended that the same blood samples should be tested by 
immunoassays for the presence of antibodies specific to 
MPO and PR3 [32]. The immunoassay technique for de-
tecting antibodies against MPO and PR3 has been im-
proved and an assay setup has advanced over the past 15 
years: capture-based assay as the second generation and 
anchor-based assay as the third generation. The currently 
available assays for MPO-ANCA and PR3-ANCA are 
highly sensitive and specific for the classification of GPA 
and MPA (high-quality immunoassays) [33]. Therefore, 
the role of IIF at the initial diagnostic tests for ANCAs is 
questioned. 
In 2017, the revised international consensus on the test-
ing of ANCAs in GPA and MPA was proposed [34] based 
on a large multi-centric study to compare the value be-
tween IIF and immunoassays for ANCA detection, which 
confirmed that the diagnosis efficiency of the anti-
gen-specific immunoassay is equal to or even exceeds that 
of IIF [35]. The 2017 revised consensus provided six rec-
ommendations as follows: Recommendation 1) a gating 
policy for requesting an ANCA test if advisable and adher-
ence to the clinical guidelines for ANCA testing is 
recommended. The clinical guidelines include glomer-
ulonephritis, diffuse alveolar hemorrhage, skin vasculitis 
and mononeuritis multiplex together with the surrogate 
markers for GPA in the 2017 EMA algorithm, 
Recommendation 2) high-quality antigen-specific assays 
for PR3-ANCA and MPO-ANCA should be used as the 
primary screening method for ANCA, Recommendation 
3) if the results for both PR3‑ANCAs and MPO-ANCAs 
are negative, and there is still a strong suspicion of 
small-vessel vasculitis, then the use of other immuno-
assays and/or indirect IIF, or referral to an experienced 
laboratory is recommended. Performing a second assay or 
IIF can also marginally increase the specificity in cases of 
low-positive test results, Recommendation 4) a diagnosis 
of ANCA-AAV cannot be excluded based on negative PR3 
ANCA and MPO-ANCA results, Recommendation 5) a 
positive PR3 ANCA and/or MPO-ANCA result only con-
tributes to the diagnostic work up for AAV and is not di-
agnostic in itself; Recommendation 6) taking the anti-
body levels into account improves the clinical inter-
pretation [34].
CONCLUSION
This review introduced the classification criteria for 
AAV, which have been proposed since 1990 and described 
efforts that have been made to overcome their limitations 
to date. The accurate methods or criteria for the classi-
fication of AAV are essential because the early classi-
fication of AAV can make it possible to expect a better 
prognosis by initiating treatment at the appropriate time. 
On the other hand, there are no current decisively diag-
nostic methods or criteria for the classification of AAV 
currently available. Future studies regarding novel serum 
biomarkers and epigenetic information for both the clas-
sification of AAV and predicting the prognosis will reduce 
the time of an accurate diagnosis of AAV. 
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